Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
The objective of this study is to explore the efficacy of ixekizumab in treating patients
with a diagnosis of non-infectious intermediate, posterior, panuveitis, or chronic
steroid-dependent anterior uveitis who had failed treatment with a classic synthetic DMARD
including methotrexate, mycophenolate, cyclosporin, azathioprine, cyclophosphamide and/or at
least one anti-TNF agent including adalimumab, infliximab, etanercept, golimumab or
certolizumab.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts Eye Research and Surgery Institution